Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Karla Therapeutics
Innovating mental health treatments through neuroimmunology

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

Active
🇫🇷 France
Karla Therapeutics
Exolvo Biosciences
Revolutionizing oral drug delivery, eliminating painful injections

Exolvo Biosciences, a collaboration between NLC Health Ventures and Verily (Google) Life Sciences, is revolutionizing oral drug delivery for large molecules like biologics. Our smart capsule technology, originating from the Google X moonshot program, eliminates painful injections and maximizes medication effectiveness. With ongoing pre-clinical testing and plans for an IND package in the U.S., we're poised to redefine drug delivery standards.

Active
🇺🇸 United States of America
Exolvo Biosciences
Garland Surgical
Novel hip implant designed to last

Garland Surgical addresses the challenge of hip replacement surgeries by offering an innovative solution that improves upon standard prostheses. Unlike traditional implants, the MaltaHip features four independent parts that provide enhanced mobility in three directions, reducing wear and minimizing the risk of dislocation. This implant offers a longer lifespan and greater functionality compared to standard prostheses. Importantly, it doesn't require a change to the normal surgical procedure, making it easier for surgeons to adopt.

Active
🇬🇧 United Kingdom
Garland Surgical
Concord Neonatal
A shock-free birth for every baby

The traditional practice of immediately cutting the umbilical cord after birth can pose risks to newborns, causing a dangerous drop in blood flow and oxygen levels. Concord Neonatal offers a solution by allowing babies to receive lifesaving care with the umbilical cord intact until they start breathing on their own. This innovation, aims to prevent birth complications and long-term disabilities, while keeping the baby close to the mother and maximizing the benefits of placental blood until the baby can breathe independently.

Active
🇳🇱 Netherlands
Concord Neonatal
Nicolab
Image analysis for the improvement of stroke treatment

Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.

Active
🇳🇱 Netherlands
Nicolab
Rheumasense
Rheumasense delivers real-time, precise RA insights with LC-MS biomarker testing and AI, empowering personalized, proactive care

Rheumasense combines LC-MS biomarker testing with advanced machine learning to provide real-time, objective insights into rheumatoid arthritis (RA) disease activity. Our technology measures specific metabolites linked to RA progression, offering accurate, quantitative data for timely, personalized treatment adjustments. With a simple at-home blood collection kit and clinically validated testing at Mayo Clinic Laboratories, we deliver actionable results quickly and cost-effectively, improving patient outcomes and supporting proactive care.

🇺🇸 United States of America
Rheumasense
Aerion Bioscience
Pioneering early lung cancer screening and saving lives

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

Active
🇱🇺 Luxembourg
Aerion Bioscience
Hapticheart Solutions
Sense of touch solution for catheter-based cardiovascular procedures

HapticHeart Solutions is revolutionizing cardiac procedures by giving cardiologists a "sense of touch" during catheter-based surgeries. These surgeries, which are becoming more complex, often require delicate maneuvers inside the heart. Their wearable device translates signals from the cath lab into tactile feedback, allowing cardiologists to feel what's happening inside the patient's heart. This helps them navigate catheters more effectively and focus on critical aspects of the procedure, leading to safer and more efficient surgeries with better outcomes for patients.

Active
🇺🇸 United States of America
Hapticheart Solutions

Our impact

15
Countries active in
€190M+
Raised by NLC ventures
20-25
Ventures built annually
2M+
Patients impacted
40+
Healthcare experts
70+
Active ventures in our portfolio

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director